Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prexasertib with Chemoradiation in Head and Neck Cancer
NCT02555644Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2016
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of prexasertib in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Maximum Tolerated Dose at 8 weeks. Started Feb 2016; status: completed.
02
Drugs
prexasertib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02555644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02555644.